Citigroup’s Phathom Pharmaceuticals PHAT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$326K Buy
29,369
+910
+3% +$11.5K ﹤0.01% 3768
2025
Q4
$472K Buy
28,459
+14,824
+109% +$212K ﹤0.01% 3602
2025
Q3
$160K Sell
13,635
-503,612
-97% -$5.2M ﹤0.01% 4082
2025
Q2
$4.96M Sell
517,247
-13,612
-3% -$75.3K ﹤0.01% 1897
2025
Q1
$3.33M Buy
530,859
+486,282
+1,091% +$2.95M ﹤0.01% 2268
2024
Q4
$362K Buy
44,577
+13,056
+41% +$162K ﹤0.01% 4043
2024
Q3
$570K Buy
31,521
+22,665
+256% +$317K ﹤0.01% 3648
2024
Q2
$91.2K Buy
8,856
+2,811
+47% +$29K ﹤0.01% 4257
2024
Q1
$64.2K Buy
6,045
+396
+7% +$3.36K ﹤0.01% 4504
2023
Q4
$51.6K Buy
5,649
+1,821
+48% +$15.7K ﹤0.01% 4499
2023
Q3
$39.7K Sell
3,828
-5,256
-58% -$72.1K ﹤0.01% 4208
2023
Q2
$130K Buy
9,084
+8,138
+860% +$93.8K ﹤0.01% 4108
2023
Q1
$6.75K Sell
946
-186
-16% -$1.63K ﹤0.01% 4868
2022
Q4
$12.7K Sell
1,132
-115
-9% -$1.19K ﹤0.01% 4767
2022
Q3
$14K Sell
1,247
-1,262
-50% -$12K ﹤0.01% 4885
2022
Q2
$21K Buy
2,509
+413
+20% +$4.25K ﹤0.01% 4977
2022
Q1
$29K Sell
2,096
-5,355
-72% -$86.5K ﹤0.01% 4969
2021
Q4
$147K Buy
7,451
+1,971
+36% +$46.4K ﹤0.01% 4532
2021
Q3
$176K Buy
5,480
+2,640
+93% +$87.7K ﹤0.01% 4181
2021
Q2
$96K Buy
2,840
+993
+54% +$35.6K ﹤0.01% 4528
2021
Q1
$69K Sell
1,847
-1,447
-44% -$60.5K ﹤0.01% 4536
2020
Q4
$110K Buy
3,294
+2,176
+195% +$88.2K ﹤0.01% 5469
2020
Q3
$41K Sell
1,118
-2,144
-66% -$74.3K ﹤0.01% 5726
2020
Q2
$107K Buy
3,262
+21
+0.6% +$807 ﹤0.01% 5520
2020
Q1
$83K Buy
3,241
+1,083
+50% +$36.2K ﹤0.01% 5509
2019
Q4
$67K Buy
+2,158
New +$54.2K ﹤0.01% 6092

Other funds holding PHAT